The 6th World Symposium on Pulmonary Hypertension: what's old is new.
genetics
hemodynamics
pulmonary hypertension
therapy
Journal
F1000Research
ISSN: 2046-1402
Titre abrégé: F1000Res
Pays: England
ID NLM: 101594320
Informations de publication
Date de publication:
2019
2019
Historique:
accepted:
11
06
2019
entrez:
29
6
2019
pubmed:
30
6
2019
medline:
2
6
2020
Statut:
epublish
Résumé
In February 2018, the 6th World Symposium on Pulmonary Hypertension (WSPH) brought together experts from various disciplines to review the most relevant clinical and scientific advances in the field of PH over the last 5 years. Based on careful review and discussions by members of the different task forces, major revisions were made on the hemodynamic definition for various forms of PH and new genes were added to the list of genetic markers associated with pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease. In addition, the use of risk stratification tools was encouraged as a strategy to reduce one-year mortality risk in PAH patients through early implementation of PAH therapies. While members of the medical community are still debating some of the proposed changes, the new WSPH guidelines advocate early diagnosis and initiation of combination therapy to reduce mortality and improve quality of life in patients with PH.
Identifiants
pubmed: 31249672
doi: 10.12688/f1000research.18811.1
pmc: PMC6584967
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL134776
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL139664
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL129970
Pays : United States
Déclaration de conflit d'intérêts
No competing interests were disclosed.Competing interests: Dr Simon is a consultant for Actelion, Complexa and received research funding from Novartis and NIH.Competing interests: Dr Sahay is serving as a speaker and consultant for Bayer, United Therapeutics and Actelion pharmaceuticals. He also has a Chest foundation grant.No competing interests were disclosed.
Références
Pathol Microbiol (Basel). 1975;43(2-O):246-7
pubmed: 1228586
Eur Respir J. 2009 Oct;34(4):888-94
pubmed: 19324955
Circ Cardiovasc Genet. 2012 Jun;5(3):336-43
pubmed: 22474227
Arthritis Rheum. 2013 Apr;65(4):1074-84
pubmed: 23280155
N Engl J Med. 2013 Jul 25;369(4):351-361
pubmed: 23883380
Nat Genet. 2014 Jan;46(1):65-9
pubmed: 24292273
Circ Res. 2014 Jun 20;115(1):189-202
pubmed: 24951767
Eur Respir J. 2014 Dec;44(6):1635-45
pubmed: 25234805
Eur Respir J. 2015 Jul;46(1):152-64
pubmed: 25837032
Chest. 2015 Oct;148(4):1043-54
pubmed: 26066077
N Engl J Med. 2015 Aug 27;373(9):834-44
pubmed: 26308684
Am J Respir Crit Care Med. 2015 Nov 1;192(9):1102-10
pubmed: 26360334
Circulation. 2016 Mar 29;133(13):1240-8
pubmed: 26873944
Chest. 2017 Apr;151(4):821-828
pubmed: 27884767
Radiology. 2017 May;283(2):381-390
pubmed: 28092203
JAMA Cardiol. 2017 Dec 1;2(12):1361-1368
pubmed: 29071338
Am J Respir Crit Care Med. 2018 Feb 15;197(4):509-516
pubmed: 29099619
Eur Respir J. 2018 Apr 4;51(4):
pubmed: 29439019
JAMA Cardiol. 2018 Apr 1;3(4):298-306
pubmed: 29541759
Eur Respir J. 2018 Apr 4;51(4):
pubmed: 29563168
Eur Respir J. 2018 Mar 29;51(3):
pubmed: 29599118
Anatol J Cardiol. 2018 Apr;19(4):273-278
pubmed: 29615545
Circ Genom Precis Med. 2018 Apr;11(4):e001887
pubmed: 29631995
Nat Commun. 2018 Apr 12;9(1):1416
pubmed: 29650961
Lancet Respir Med. 2019 Mar;7(3):227-238
pubmed: 30527956
Drug Discov Today. 2019 Mar;24(3):703-716
pubmed: 30529762
Eur Respir J. 2019 Jan 24;53(1):null
pubmed: 30545968
Eur Respir J. 2019 Jan 24;53(1):null
pubmed: 30545971
Eur Respir J. 2019 Jan 24;53(1):null
pubmed: 30545973
Eur Respir J. 2019 Jan 24;53(1):null
pubmed: 30552088
Circ Res. 2019 Mar 15;124(6):904-919
pubmed: 30661465
Chest. 2019 Feb 14;:null
pubmed: 30772387